Literature DB >> 22665359

Oral muscle relaxant may induce immediate allergic reactions.

Gyu-Young Hur1, Eui Kyung Hwang, Jae-Young Moon, Young-Min Ye, Jae-Jeong Shim, Hae-Sim Park, Kyung-Ho Kang.   

Abstract

Eperisone and afloqualone act by relaxing both skeletal and vascular smooth muscles to improve circulation and suppress pain reflex. These drugs are typically prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) as painkillers. However, there have been no reports on serious adverse reactions to oral muscle relaxants; and this is the first report to describe three allergic reactions caused by eperisone and afloqualone. All three patients had histories of allergic reactions after oral intake of multiple painkillers, including oral muscle relaxants and NSAIDs, for chronic muscle pain. An open-label oral challenge test was performed with each drug to confirm which drugs caused the systemic reactions. All patients experienced the same reactions within one hour after oral intake of eperisone or afloqualone. The severity of these reactions ranged from laryngeal edema to hypotension. To confirm that the systemic reaction was caused by eperisone or afloqualone, skin prick testing and intradermal skin tests were performed with eperisone or afloqualone extract in vivo, and basophil activity tests were performed after stimulation with these drugs in vitro. In one patient with laryngeal edema, the intradermal test with afloqualone extract had a positive result, and CD63 expression levels on basophils increased in a dose-dependent manner by stimulation with afloqualone. We report three allergic reactions caused by oral muscle relaxants that might be mediated by non-immunoglobulin E-mediated responses. Since oral muscle relaxants such as eperisone and afloqualone are commonly prescribed for chronic muscle pain and can induce severe allergic reactions, we should prescribe them carefully.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665359      PMCID: PMC3381482          DOI: 10.3349/ymj.2012.53.4.863

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  9 in total

1.  Non-pigmenting fixed drug eruption: a new case due to eperisone hydrochloride.

Authors:  C Choonhakarn
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

2.  [A case of eperisone hydrochloride (myonal)--induced drug eruption leading to erythema and angioedema].

Authors:  Takashi Ueno; Seiji Kawana
Journal:  Arerugi       Date:  2007-07

3.  Fixed drug eruption due to afloqualone: the first reported case.

Authors:  T Demitsu; Y Tomita
Journal:  J Dermatol       Date:  1998-02       Impact factor: 4.005

Review 4.  Anaphylaxis: a review of 601 cases.

Authors:  Luke M Webb; Phil Lieberman
Journal:  Ann Allergy Asthma Immunol       Date:  2006-07       Impact factor: 6.347

5.  Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats.

Authors:  M Matsunaga; Y Uemura; Y Yonemoto; K Kanai; H Etoh; S Tanaka; Y Atsuta; Y Nishizawa; Y Yamanishi
Journal:  Jpn J Pharmacol       Date:  1997-03

6.  Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans.

Authors:  S Iwase; T Mano; M Saito; G Ishida
Journal:  Funct Neurol       Date:  1992 Nov-Dec

7.  Anaphylactic reactions to tolperisone (Mydocalm).

Authors:  Camillo Ribi; Christophe Vermeulen; Conrad Hauser
Journal:  Swiss Med Wkly       Date:  2003-06-28       Impact factor: 2.193

8.  Pharmacological studies on 6-amino-2-fluoromethyl-3-(O-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity.

Authors:  T Ochiai; R Ishida
Journal:  Jpn J Pharmacol       Date:  1982-06

9.  Mechanisms of action of eperisone on isolated dog saphenous arteries and veins.

Authors:  S Inoue; K Bian; T Okamura; H Okunishi; N Toda
Journal:  Jpn J Pharmacol       Date:  1989-07
  9 in total
  2 in total

1.  Current practice for diagnosing immediate drug hypersensitivity reactions in Korea.

Authors:  Sung-Yoon Kang; Min-Suk Yang; Woo-Jung Song; Sang-Heon Cho
Journal:  Korean J Intern Med       Date:  2021-01-05       Impact factor: 2.884

Review 2.  Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity.

Authors:  Woo-Jung Song; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2013-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.